Board of Directors

PAUL R. CARTER

Paul R. Carter is a seasoned international biopharmaceutical leader with over 25 years of senior executive experience, specializing in commercialization, regional alliances, and mergers and acquisitions. Mr. Carter is currently a Board Director for four publicly listed biopharma companies, which include HutchMed PLC, Mallinckrodt Pharmaceuticals plc, Immatics NV, and VectivBio Inc. He is also a member of the board of directors of several private companies, including Evox Therapeutics Ltd. Previously, Mr. Carter was the Executive Vice President and Chief Commercial Officer of Gilead Sciences Inc., where he was responsible for the company's worldwide commercial strategy and execution, including generating $33 billion of revenue in 2015 and launching several of the best-selling prescription drugs of all time. Prior to that, Mr. Carter held senior leadership roles in GSK, including head of GSK China and head of Smith Kline Beecham Russia. Mr. Carter is a Fellow of the Chartered Institute of Management Accountants in the UK and holds a degree in Business Studies from the University of West London.

JONATHAN R. LYNCH

Jonathan R. Lynch currently manages Incisive Capital, which participated as the leading new investor in the company’s Dec2021 convertible note financing. Mr. Lynch founded and previously served as a Managing Director and Investment Committee member of CCMP Capital Advisors, LLC (successor to JPMorgan Partners). At CCMP, he focused principally on private equity investments in the consumer and business services sectors. Prior to joining CCMP in 1992, Mr. Lynch was a member of the Mergers and Acquisitions department of Prudential Securities and is a past president of the Venture Investors Association of NY (VIANY). He graduated magna cum laude with a B.S. from Georgetown University and holds an MBA from Harvard Business School.

THOMAS B. KING

Thomas B. King has served as a director of the Company since 2017 and Executive Chair since 2018. Mr. King brings a wealth of knowledge from 40+ years of experience in biopharma leadership positions ranging from large to development-stage companies. Mr. King has built, operated and sold multiple public specialty pharmaceutical businesses, and has including most recently serving as interim CEO for VIVUS, Inc. (Nasdaq: VVUS), from December 2017 to April 2018. He has served as an independent biotechnology consultant and advisor since August 2016.

Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from June 2003 to August 2016 when it was acquired by Grupo Ferrer. From October 2015 to August 2016, Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately held biopharmaceutical development stage company. From January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation, a publicly traded pharmaceutical company, including President and Chief Operating Officer from January 1995 to January 1997 and President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors from January 1995 until it was acquired by Cephalon, Inc.

Mr. King currently serves on the board of directors of Achieve Life Sciences, Inc. and TFF Pharmaceuticals, Inc., both publicly traded specialty pharmaceutical companies and Kinaset Therapeutics, Inc., a privately held biotechnology company.

Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.

FRANK J. BELLIZZI, DMD

Frank Bellizzi has over 25 years of experience, within and beyond Life Sciences, as an operator, consultant and advisor leading business transformation and growth. Immediately prior to Concentric, Dr. Bellizzi was CEO of HydraDx, a saliva-based platform for real time health monitoring using a connected device. Dr. Bellizzi also served as President of Zila Pharmaceuticals (NASDAQ: ZILA) where he successfully created and implemented a strategy to build an oral cancer detection business, growing its flagship product, ViziLite® Plus, into the leading oral cancer detection test in the U.S. and internationally.

In addition, as Chief Financial Officer and Chief Operating Officer of Streampipe, a rich media software company, Dr. Bellizzi engineered all aspects of the company’s growth and successful sale to Loudeye (NASDAQ: LOUD).

Earlier in his career, as a member of Booz, Allen & Hamilton’s Health Industries Practice, Dr. Bellizzi facilitated a number of high-profile engagements, including the merger and integration of two leading West Coast health systems, the acquisition strategy for a leading New York health system, and the operational revitalization of the Australian health care system.

Dr. Bellizzi earned his MBA from the Wharton School of the University of Pennsylvania, his DMD from the University of Pennsylvania School of Dental Medicine, and his BS from Georgetown University.

JOHN DONOVAN, MD MBA

John Donovan is a board certified anesthesiologist with 25 years of experience in clinical medicine and 14 years of experience working with life science companies  Dr. Donovan has held a number of senior business development positions for anesthesia/pain biotechs, including Signature Therapeutics and Anesiva (NASDAQ: ANSV).

Previously, Dr. Donovan built and ran a large anesthesiology medical practice, East Bay Anesthesiology Medical Group, which provides anesthesia and perioperative medical services to hospitals in the Sutter Health system. Dr. Donovan has conducted research and published on postsurgical pain management, including the use of continuous peripheral nerve blocks for TKA, and has also served as an advisor to a variety of emerging life science businesses. Dr. Donovan completed his residency in anesthesiology at the University of California San Francisco where he was chief resident and continues to maintain an active faculty appointment. He served as  a diving medical officer in the U.S. Navy and has been involved with global health efforts in Haiti since the 2010 earthquake.

Dr. Donovan earned BS and MD degrees from Georgetown University and an MBA from the Haas School of Business at the University of California Berkeley.